Week Ending April 4, 2022

Collaboration Finds International Disparities in Screening, Treatment, and Outcomes for Patients With Lung Cancer
A consensus reached by a lung cancer clinical community within the International Cancer Benchmarking Partnership (ICBP) presented by Lynch et al at the European Lung Cancer Congress (Abstract 196P) has highlighted international disparities in the management and outcomes of patients with lung cancer in high-income countries.”

Stage Shift Seen With CT Screening for Lung Cancer in the U.S.
“Stage shift toward Stage I NSCLC observed following introduction of low-dose CT screening for lung cancer”

Adjuvant Pembrolizumab Improves DFS in Early-Stage Non-Small Cell Lung Cancer
“Adjuvant pembrolizumab can prolong disease-free survival (DFS) after surgical resection in patients with early stage non-small cell lung cancer (NSCLC), according to results of the phase 3 PEARLS/KEYNOTE-091 study.”

First-Line TKI Plus Up-Front Local Radiotherapy Improves Survival in EGFR+ NSCLC
“Patients with EGFR-mutated non–small cell lung cancer had an improved survival benefit following treatment with a first-line tyrosine kinase inhibitors plus up-front local radiotherapy.”

First-Line Tiragolumab Combo Misses PFS Co-Primary End Point in ES-SCLC
“Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.”

Substantial Burden of Myelosuppression With Trilaciclib and Chemotherapy for ES-SCLC
“Use of trilaciclib prior to chemotherapy demonstrated a substantial burden of myelosuppressive hematologic adverse events within the patients with extensive-stage small-cell lung cancer.”

The effects of severe COVID-19 on the lungs after one year
“While short-term lung damage has been reported in patients hospitalized with pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is little data on the more chronic sequelae of this condition. A new research paper summarizes data from patients seen one year from discharge.”